Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Cash Flow-to-Debt Ratio
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd cash flow-to-debt ratio. Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of CN¥-149.12 Million could theoretically repay 0% of its total liabilities (CN¥4.74 Billion) in one year. Check Hunan Dajiaweikang Pharmaceutical Indust earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2025)
Cash flow-to-debt ratio of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2025. Historical debt coverage capacity for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd across 7 annual periods. Check 301126 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Cash Flow-to-Debt Ratio by Year (2019–2025)
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd. For the full cash flow conversion analysis, see Hunan Dajiaweikang Pharmaceutical Indust cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.03x | CN¥-149.12 Million | CN¥4.74 Billion | ▼ -666.1% |
| 2024 | 0.01x | CN¥24.04 Million | CN¥4.33 Billion | ▼ -28.4% |
| 2023 | 0.01x | CN¥27.13 Million | CN¥3.50 Billion | ▲ +103.3% |
| 2022 | -0.23x | CN¥-493.96 Million | CN¥2.11 Billion | ▼ -89.9% |
| 2021 | -0.12x | CN¥-161.81 Million | CN¥1.32 Billion | ▲ +5.7% |
| 2020 | -0.13x | CN¥-151.46 Million | CN¥1.16 Billion | ▼ -199.7% |
| 2019 | 0.13x | CN¥135.91 Million | CN¥1.04 Billion | — |